-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | None |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | 1B |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | nan |
| Dividend Yield | None |
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. The company was incorporated in 2018 and is based in Fremont, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ALMR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026